Clinsights: Making Information A Competitive Advantage
Clinsights uses advanced information systems technology to aggregate population-based clinical outcomes data, and to disseminate this data to device companies and physicians. The company's data collection services include e-registries for clinical research, outcomes databases at key clinical centers, and post-market surveillance studies, and the information is disseminated through specialty websites and Internet-based data systems.Key to Clinsights' approach is building relationships with thought leaders in different clinical specialties, the first of which is interventional cardiology. In this area, Clinsights is working with the Cardiovascular Research Foundation (CRF), sponsors of the leading interventional cardiology conference, the Transcatheter Cardiovascular Therapeutics (TCT) meeting. This partnership has produced Clinsights' first website, TCTMD.com.Clinsights' bet is that it can convince medical device companies of the value of its services, built around the ability to collect and disseminate information, and enhanced by partnerships with leading physicians, in providing a competitive advantage that can help differentiate products and technologies.
You may also be interested in...
For years, companies have offered remote data entry systems to transfer data from trial sites to a central server. But Big Pharma has by and large stuck to its old-fashioned paper ways. Now several start-ups are offering a new breed of web-based RDE and the pharmaceutical industry is starting to take interest. But before embracing an online approach to data collection, drug companies want proof that doing so will save them time and money. Pharma companies must also evaluate how to integrate data collection and management into the rest of their infrastructures. Collaboration rather than competition might best enable pharmaceutical; companies to fully realize the benefits of web-enabled trials through the cooperative sharing of resources.
The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.
Big pharma has faced many evolutions to the pharma playbook of old. New technologies such as wearables introduce behavioral change to patients, while e-commerce giants such as Amazon seek a piece of the Rx action. The health care industry has done a reasonable job of weathering the storm inflicted on its core business model over the years, but it has yet to be a true disruptor. As the world marches on is pharma’s choice to disrupt, or inevitably be disrupted for good?